Literature DB >> 19034039

Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration.

Young Jin Kim1, Hee Kyung Hong, Hui Sun Lee, Sang Hyun Moh, Jong Cook Park, Su Hyun Jo, Han Choe.   

Abstract

Papaverine, a vasodilator used as a therapeutic agent for a range of diseases, has been reported to increase the risk of occasional serious ventricular arrhythmias. To examine the mechanism for this effect, we herein tested the effects of papaverine on human ether-a-go-go (HERG) K channels expressed in HEK293 cells and Xenopus oocytes. Our results revealed that papaverine dose-dependently decreased the tail currents of HERG channel expressed in HEK293 cells with the IC50 and the Hill coefficient of 0.58 microM and 0.58, respectively, at +20 mV and 36 degrees C. The IC50 for the papaverine-induced blockade of HERG current in Xenopus oocytes was found to decrease progressively relative to depolarization (38.8, 30.0, and 24.8 microM at -10, +20, and +40 mV, respectively). The papaverine-induced blockade of HERG current was time-dependent; the fractional current was 0.92 +/- 0.03 of the control at the beginning of the pulse, but it declined to 0.18 +/- 0.06 after 6 seconds at a test potential of 0 mV. These results collectively indicate that papaverine blocks HERG channel in a concentration-, voltage-, and time-dependent manner. Two S6 domain mutations, Y652A and F656A, partially attenuated (Y652A) or abolished (F656A) the hERG current blockade, suggesting that papaverine blocks HERG channel at the pore of the channel. This was consistent with the computational simulation that showed papaverine interacts with Tyr652 and Phe656. Therefore, ventricular arrhythmias induced by papaverine could be resulted from the blockage of the HERG channel at the cardiac myocytes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19034039     DOI: 10.1097/FJC.0b013e31818e65c2

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.

Authors:  Rashmi R Shah; Peter D Stonier
Journal:  Ther Adv Drug Saf       Date:  2018-06-18

2.  Evaluation of the risk factors for ventricular arrhythmias secondary to QT prolongation induced by papaverine injection during coronary flow reserve studies using a 4 Fr angio-catheter.

Authors:  Yoshitaka Okabe; Kanichi Otowa; Yasuhito Mitamura; Hisayoshi Murai; Soichiro Usui; Shuichi Kaneko; Masayuki Takamura
Journal:  Heart Vessels       Date:  2018-04-30       Impact factor: 2.037

Review 3.  Natural products modulating the hERG channel: heartaches and hope.

Authors:  Jadel M Kratz; Ulrike Grienke; Olaf Scheel; Stefan A Mann; Judith M Rollinger
Journal:  Nat Prod Rep       Date:  2017-08-02       Impact factor: 13.423

4.  Ligand-based prediction of hERG-mediated cardiotoxicity based on the integration of different machine learning techniques.

Authors:  Pietro Delre; Giovanna J Lavado; Giuseppe Lamanna; Michele Saviano; Alessandra Roncaglioni; Emilio Benfenati; Giuseppe Felice Mangiatordi; Domenico Gadaleta
Journal:  Front Pharmacol       Date:  2022-09-05       Impact factor: 5.988

5.  The protective effect of Papaverine and Alprostadil in rat testes after ischemia and reperfusion injury.

Authors:  Mehmet Ali Karagoz; Omer Gokhan Doluoglu; Hatice Ünverdi; Berkan Resorlu; Mehmet Melih Sunay; Arif Demirbas; Tolga Karakan; Arif Aydin
Journal:  Int Braz J Urol       Date:  2018 May-Jun       Impact factor: 1.541

Review 6.  HPLC-based activity profiling for pharmacologically and toxicologically relevant natural products - principles and recent examples.

Authors:  Matthias Hamburger
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.